Madrigal Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Madrigal Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Madrigal Pharmaceuticals generated $23.3 million of operating cash flow and spent $4.3 million on capital expenditures. That left free cash flow of $19.1 million, a free-cash-flow margin of 5.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Madrigal Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -57.94M | -94.39M | -58.58M | -114.19M | -42.28M | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M | -112.19M | -98.74M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 381.00K | 386.00K | 392.00K | 358.00K | 377.00K | 379.00K | 363.00K | 298.00K | 267.00K | 168.00K | 142.00K | 135.00K |
| Stock-Based Compensation | 35.37M | 34.02M | 25.79M | 26.25M | 25.16M | 20.93M | 17.68M | 17.90M | 24.40M | 19.90M | 14.85M | 12.66M |
| Change in Working Capital | 32.48M | -107.84M | -104.87M | 162.90M | -32.19M | -40.31M | -50.31M | 21.26M | 1.76M | -20.96M | 18.84M | -84.00K |
| Operating Cash Flow | 23.33M | -167.44M | -133.46M | 79.85M | -47.05M | -88.89M | -104.49M | -66.98M | -134.94M | -149.16M | -79.93M | -84.92M |
| Capital Expenditures | -4.25M | -3.85M | 390.00K | -857.00K | 0 | 0 | -195.00K | -779.00K | -131.00K | -357.00K | -1.04M | -339.00K |
| Investing Cash Flow | 34.20M | 192.19M | 27.58M | -207.00M | 47.86M | 163.88M | -47.95M | -202.39M | -122.10M | 98.05M | -362.12M | 50.20M |
| Financing Cash Flow | 3.11M | 2.33M | 8.96M | 236.65M | 1.74M | 8.64M | 19.77M | 7.46M | 134.12M | 573.71M | 479.92M | 19.58M |
| Net Change in Cash | 60.69M | 28.41M | -96.91M | 109.50M | 2.55M | 83.63M | -132.66M | -261.91M | -122.92M | 522.60M | 37.86M | -15.14M |
| Free Cash Flow | 19.08M | -171.28M | -133.07M | 78.99M | -47.05M | -88.89M | -104.68M | -67.76M | -135.08M | -149.51M | -80.97M | -85.26M |
This table shows 12 quarterly periods of Madrigal Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MDGL's reporting calendar. What is a cash flow statement?